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Abstract Non-alcoholic steatohepatitis (NASH), also known as fatty liver disease (FLD), is a 
major public health problem. It is considered to be the hepatic manifestation of the 
metabolic syndrome. Chronic inflammation of the liver is an essential key in the 
progression from simple hepatic steatosis to steatohepatitis, the evolutionary stage of 
fatty liver disease. Moreover, the innate immune system plays a crucial role in the 
progression of hepatic inflammation. For this reason, it is of utmost importance to 
elucidate the connections between immune mechanisms, Toll-like receptor cytokine 
signalling, in order to find new effective treatments. 
Further studies are necessary to test theories presented in this paper. The elucidation 
of mechanisms underlying the progression of hepatic steatosis towards steatohepatitis is 
essential for the development of useful diagnosis and treatment for medical practice.  
Keywords  non-alcoholic steatohepatitis, NASH pathogenesis, immune mechanism, Toll-like 
receptors (TLRs), Interleukin-17 (IL-17) 
Highlights  One of the possible mechanisms responsible for the activation of the immune system 
through intestinal microbiota is the activation of IL17 axis. 
 Another possibility is represented by activation of the TLRs, with further studies being 
necessary to clarify these perspectives. 
Sorina Cezara Coste et al. 
 53 
Introduction 
NASH is a disease considered to be the liver 
manifestation of the metabolic syndrome (MS) (1). Its 
incidence and prevalence are continually increasing 
worldwide. The prevalence of NASH in the European 
general population is between 20-30% and reaches 90% 
among patients with associated obesity (2). NASH has the 
potential of advancing to hepatic cirrhosis and increases 
the risk of developing hepatocellular carcinoma (HHC) 
(2). Due to the alarming increase in the incidence of 
obesity associated with NASH and its potential to 
progress towards severe chronic hepatic diseases (hepatic 
cirrhosis and HHC), it has been estimated that NASH will 
become one of the main causes of liver transplant (3). 
Sustained inflammatory process in the liver is essential 
for the progression from NAFLD to NASH. 
Recent medical research has reported important 
progress in understanding the immune and inflammatory 
mechanisms involved in NASH (4).    
Discussions 
Hepatic cell population  
The liver is made up of a variety of cells involved in 
the propagation of the inflammatory process. Hepatocytes 
represent 60-80% of the total liver cell population and are 
responsible for the metabolic process, biosynthesis, 
biliary secretion, and detoxification. Apart from these, in 
the liver, there are also cells with a role in immunity, such 
as Kupffer cells (KC) responsible for innate immunity, 
macrophages, and natural killer (NK) cells. After liver 
injury, other cells are recruited. Some examples are 
neutrophils, leukocytes, monocytes, and macrophages, 
also responsible for the innate immune response. The 
acquired immune response belongs to T NK cells and B 
cells. Other cell types that contribute to the production of 
inflammation and fibrosis are hepatic stellate cells (HSC) 
and sinusoidal endothelial cells (5). 
Toll-like receptors (TLRs) and interleukin 17 (IL-17)  
In the liver, TLRs are expressed through Kupffer cells, 
hepatocytes, stellate cells, and sinusoidal endothelial 
cells. They are found in different cellular locations. TLR 
2, 4, 5, 6, and 11 have extracellular location, while TLR 
3, 7, 8, and 9 are expressed intracellularly in endosomes, 
lysosomes, and the endoplasmic reticulum (6). TLR 4 is 
the most studied TLR (7). From the family of ten TLRs 
discovered in humans, TLR4 was the first to be identified 
(8). 
IL-17 is the generic name for a cytokine family 
composed of 6 members (IL-17A, IL-17B, IL-17C, IL-
17D, IL-17E and IL-17F). Interleukin 17A, which names 
the family, is secreted in the skin, liver, and mucous 
membranes (9). 
NASH pathogenesis   
The theory of the two aggressions or the theory of 
multiple hepatic aggressions has been formulated. The 
first aggression in NASH is caused by modifications in 
the metabolism of fatty acids, which leads to 
accumulation of lipids in hepatocytes and to the 
occurrence of hepatic steatosis. Lipopolysaccharides 
(LPSs), oxidative stress, cytokine production, and other 
pro-inflammatory mediators represent the second 
aggression that sustains the progression of steatosis to 
steatohepatitis (10).  
Obesity and NASH pathogenesis   
Adipose tissue is considered to have an endocrine and 
immunological function (11).  
The incidence of overweight and obesity has increased 
worldwide, from 857 million in 1980 to 2.1 trillion in 
2013 (12). Obesity is associated with atherosclerosis in 
cardiovascular diseases, Alzheimer's disease, type-2 
diabetes mellitus, and metabolic syndrome (13). The 
incidence of metabolic syndrome is continually 
increasing, because of unhealthy lifestyle changes in the 
general population – an increasing consumption of fast 
foods, high-fat diets and processed foods, a sedentary life 
style, and lack of physical exercise (14).   
In obesity, there is dysfunctional adipose tissue 
resulting from the infiltration of macrophages and 
hypertrophic adipocytes (15). The liver is the major target 
for adipose tissue accumulation and, thus, the occurrence 
of steatohepatitis. Therefore, adipose tissue is considered 
to have a major role in NASH. 
Different studies conducted on laboratory mice with 
obesity have shown that pro-inflammatory pathways are 
activated in the fat tissue in both obesity and NASH. 
Their activation involves a multifactorial process and 
includes the presence of oxidative stress which leads to 
hypoxia and adipocytes death (16), changes in the 
intestinal microbiota with increased intestinal 
permeability, and metabolic endotoxemia (17, 18). 
Obesity and NAFLD progression are associated with 
dysbiosis in the intestinal microbiota (19). Furthermore, 
experimental studies on animal models with diet-induced 
obesity have shown that intestinal microbiota is essential 
in the development of obesity and that it could play an 
important role in modulating NAFLD progression (20).     
Two of the most common mechanisms in NASH 
pathogenesis involve the immune and inflammatory 
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pathways. The inflammatory pathways are represented by 
cytokines with a pro-inflammatory role (interleukins (IL), 
while increased free fatty acid (FFA) concentration or 
bacterial products (lipopolysaccharide-LPS) activate the 
innate immune system from adipocytes and macrophages 
through Toll-like receptors (TLRs) (Figure 1) and 
ultimately lead to inflammation (18). Also, the increasing 
level of free fatty acids in blood circulation leads to their 
growth in the portal system, thus contributing to the 
development of NAFLD or NASH (15).   
 
Figure 1. Toll-like receptor (TLR) activation 
As a consequence of activating the above pro-
inflammatory pathways, adipocyte death occurs, 
producing cytokines and chemokines with a key role in 
the inflammatory process. Also, as a secondary 
consequence, other immune cells are recruited: 
neutrophils, eosinophils, dendritic cells, natural-killer 
(NK) cells, T cells, B cells etc. (13).  
Changes in the intestinal microbiota, TLR pathways 
and NASH pathogenesis 
One of the main concerns of the scientific community 
is the role of intestinal microbiota and probiotics in liver 
diseases. It is known that patients with NAFLD present an 
increase in intestinal permeability and an increased 
incidence of bacterial development in the small intestine 
compared to patients without liver disease (21). Bacterial 
translocation promotes the inflammatory process of the 
liver by activating TLRs (22). There are two known 
patterns for TLR activation: pathogen-associated 
molecular patterns (PAMPs) and damage-associated 
molecular patterns (DAMPs).  
PAMPs originate from certain exogenous pathogens 
responsible for the emergence of inflammation and 
contain lipids, lipoproteins, nucleic acids, and proteins. 
They are expressed by bacteria, viruses, parasites, and 
fungi (6). This pathway contributes to the inflammatory 
process in NASH by signaling the pathogen recognition 
receptors (PRRs), leading to the activation of innate and 
acquired immune systems. PAMPs are recognized by 
numerous PRRs receptors, including Toll-like receptors 
(TLRs) (6). 
DAMPs, similar to PAMPs, are endogenous 
molecules released by destroyed cells that trigger a sterile 
inflammatory response. In NASH, there is chronic 
inflammation resulting from the presence of DAMP. 
Similar to PAMPs, DAMPs activate both types of 
immunity, i.e., acquired and innate, and PRRs, out of 
which the most characteristic are TLRs (23). The DAMP 
receptors responsible for TLR activation are hyaluronic 
acid, fibrinogen, and thermal shock proteins (23). 
 
Figure 2. TLRs recognize a wide range of PAMPs. 
Once a molecular pattern has been recognized by 
TLR, it initiates signals with a role in activating the 
inflammatory and antiviral responses. Some 
examples are the activation of the Kappa B Nuclear 
transcription factor (NF-kb) and the regulatory 
factors of interferon which determine the 
transcription of inflammatory cytokines, chemokine 
or type-1 interferon (6) 
Different studies have attempted to elucidate the role 
of TLR4 in NASH. Patients or laboratory mice with 
NASH presented increased serum levels of 
polysaccharides, which would suggest an increased 
activation of TLR4 (24). It is also supposed that fructose 
could increase activation of TLR4 by its influence on 
microbiota and intestinal permeability. It is a risk factor 
for steatosis and steatohepatitis (25).  
The activation of TLR4 and sensitization of hepatic 
stellate cells could be the key connection between the 
inflammatory process and the emergence of fibrosis in 
NASH or other forms of chronic hepatitis. The 
explanation could be the involvement of hepatic stellate 
cells in regulating the extracellular matrix and the 
regeneration of liver tissue (8). 
Immune cells and IL-17 contribution to NASH 
pathogenesis 
The innate immune response, consisting of Kupffer 
cells (KC), neutrophils, dendritic cells (DCs), and natural 
killer cells (NKT) plays an important role in the 
pathogenesis of NASH in NAFLD (26). Having 
characteristics of both innate and acquired immune cells, 
NKTs are considered to be the link between the two 
immune systems. NKTs are found predominantly in the 
Sorina Cezara Coste et al. 
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liver and regulate the immune response through the 
secretion of cytokines TH1 and TH2 (27). T helper 17 
cells (TH17) are a subdivision of T cells that secrete IL-
17 and play a role in mediating the immune response by 
modulating the clearance of pathogens and the 
inflammatory response of tissues.  
In acute or chronic liver disease, KCs are activated by 
PAMPs and DAMPs and release cytokines with pro-
inflammatory roles, such as tumor necrosis factor (TNFa), 
interleukin-6 (IL-6), and interleukin-1b (IL-1b), 
responsible for the activation of T cells, stellate cells 
which eventually lead to apoptosis (26). The activation of 
neutrophils determines the release of pro-inflammatory 
cytokines and myeloperoxidase responsible for the 
occurrence of oxidative stress in the liver (28). Neutrophil 
high concentrations compared to lymphocytes have a role 
in the progression of NASH (29). A decrease in DCs 
results in the unfavorable evolution of NASH, suggesting 
that DCs play an important role in steatohepatitis (30). 
Natural killer T cells (NKT) are a subdivision of 
lymphocytes presenting markers for NK cells: CD161 and 
CD94 and T cell receptors (27). 
Recent studies have shown the importance of TH17 
cells in autoimmune liver disease, viral hepatitis, 
alcoholic steatohepatitis, and hepatocarcinoma (31). Tang 
et al. (32) demonstrated an increase in the number of 
TH17 cells at the hepatic level after 8 weeks of 
hypercaloric diet as well as the fact that these cells are 
associated with the progression of hepatic steatosis and 
inflammation through the production of Interleukin 17 
(IL-17).  
A delayed or ineffective immune response results in 
viral, bacterial, or fungal infections. But a heightened 
response can be harmful, as observed in autoimmune 
diseases: rheumatoid arthritis, type-1 diabetes, psoriasis, 
and inflammatory bowel diseases (33). The pathogenesis 
of these autoimmune disorders is related to the excessive 
production of pro-inflammatory cytokines: TNF-alpha, 
IL-6, IFN-gamma, IL-23 etc. (34). 
 
Figure 3. IL-17 role in the pathogenesis of NASH 
Special interest has been paid to interleukin 17 (IL-17) 
which plays an important role in the pathogenesis of 
NASH (Figure 3) (35). The classical conceptualization 
claims that under the action of certain stimuli, ThCD4 + 
lymphocytes are differentiated in TH1 lymphocytes and 
TH2 lymphocytes. It has recently been found that under 
the influence of IL-23, ThCD4 + lymphocytes 
differentiate in a specific cell type whose main action is to 
release IL-17, in addition to tumor necrosis factor (TNF) 
and granulated monocyte colonies stimulation factor 
(GM-CSF) (9). The lymphocytes of this distinct subset of 
TH1 and TH2 were called Th17 lymphocytes. Apart from 
Th17 lymphocytes, additional synthesis sources of IL-17 
are lymphocytes THCD8 + neutrophils, NK and NKT 
cells, macrophages etc. (36). Increased levels of IL-17A 
were discovered in liver disorders such as alcoholic 
steatohepatitis (37), viral hepatitis B and C (9, 38), 
primary biliary cirrhosis (39), hepatocellular carcinoma 
(40). The increased expression of IL-17A is also found in 
patients with obesity and is associated with an increased 
infiltration of adipose tissue with TH17 (41). 
Conclusions 
One of the possible mechanisms responsible for the 
activation of the immune system through intestinal 
microbiota is the activation of IL17 axis. The other one is 
the activation of the TLRs. Further studies are necessary 
to test these possibilities.  
The elucidation of mechanisms underlying the 
progression of hepatic steatosis towards steatohepatitis is 
essential for the development of useful diagnosis and 
treatment for medical practice. 
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